ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Ash Stevens to make cancer drug ingredients

May 31, 2004 | APPEARED IN VOLUME 82, ISSUE 22

Ash Stevens will manufacture 5-azacitidine, the active ingredient in Pharmion's Vidaza, a recently approved treatment for the blood cancer myelodysplastic syndromes. According to Ash Stevens CEO Stephen A. Munk, his firm developed 5-azacitidine in partnership with its discoverer, the National Cancer Institute. Ash Stevens recently received FDA approval to make bortezomib, the active ingredient in Millennium Pharmaceutical's bone marrow cancer drug Velcade, and Munk expects approval later this year to make clofarabine, the active ingredient in Genzyme's Clofarex, a pediatric leukemia drug.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment